Skip to main content

Table 2 The Most Common Patients’ Clinical Status on Study Days 1, 3, 7, and 14

From: Efficacy and safety of Levamisole treatment in clinical presentations of non-hospitalized patients with COVID-19: a double-blind, randomized, controlled trial

Clinical Presentation

Placebo/Routine Care

Levamisole/ Routine Care

P value

N (%)

N (%)

Fever

 Day 1

20 (80.0)

24 (96.0)

0.189

 Day 3

20 (80.0)

24 (96.0)

0.189

 Day 7

3 (12.0)

0 (0.0)

0.235

 Day 14

0 (0.0)

0 (0.0)

1.000

Cough

 Day 1

17 (68.0)

22 (88.0)

0.088

 Day 3

17 (68.0)

23 (92.0)

0.034

 Day 7

17 (68.0)

15 (60.0)

0.556

 Day 14

9 (36.0)

1 (4.0)

0.005

Dyspnea

 Day 1

13 (52.0)

14 (56.0)

0.777

 Day 3

13 (52.0)

14 (56.0)

0.777

 Day 7

12 (48.0)

4 (16.0)

0.015

 Day 14

0 (0.0)

7 (28.0)

0.010

Asthenia

 Day 1

5 (20.0)

4 (16.0)

0.490

 Day 3

5 (20.0)

2 (8.0)

0.235

 Day 7

4 (16.0)

1 (4.0)

0.235

 Day 14

3 (12.0)

0 (0.0)

0.235

Headache

 Day 1

2 (8.0)

2 (8.0)

1.000

 Day 3

2 (8.0)

2 (8.0)

1.000

 Day 7

1 (4.0)

0 (0.0)

1.000

 Day 14

1 (4.0)

0 (0.0)

1.000

Dizziness

 Day 1

2 (8.0)

1 (4.0)

1.000

 Day 3

2 (8.0)

1 (4.0)

1.000

 Day 7

2 (8.0)

0 (0.0)

0.490

 Day 14

2 (8.0)

0 (0.0)

0.490

Myalgia

 Day 1

3 (12.0)

2 (8.0)

0.235

 Day 3

3 (12.0)

2 (8.0)

0.235

 Day 7

3 (12.0)

0 (0.0)

0.235

 Day 14

2 (8.0)

0 (0.0)

0.490

Nausea

 Day 1

2 (8.0)

1 (4.0)

1.000

 Day 3

2 (8.0)

1 (4.0)

1.000

 Day 7

1 (4.0)

1 (4.0)

1.000

 Day 14

1 (4.0)

0 (0.0)

1.000